This tasty formula is designed to mix easily with water
The semaglutide segment held a dominant market share in 2023, with projections indicating sustained growth through 2032
Its also approved for those with a BMI of 27 or greater who have a weight-related medical condition
Data from randomized controlled trials suggest that withdrawing either glucagon-like peptide-1 (GLP-1) receptor agonists or dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonists leads to a substantial regain of lost weight
: SURMOUNT ,
Other reasons to contact your provider include: Weight loss that significantly exceeds your prescribed treatment plan Cold sensations accompanied by sweating, tremor, or confusion (possible hypoglycemia, especially if taking insulin or sulfonylureas) Persistent fatigue with pallor or weakness (possible anemia) Severe or persistent symptoms that significantly impact quality of life or do not improve with conservative measures Your healthcare provider can assess whether symptoms represent expected physiological adaptation, require investigation for alternative causes (including blood tests for thyroid function, complete blood count, iron studies, or vitamin B12 levels), or indicate a need for medication adjustment